Analysis of the pan-Asian subgroup of patients in the NALA Trial: a randomized phase III NALA Trial comparing neratinib+capecitabine (N+C) vs lapatinib+capecitabine (L+C) in patients with HER2+metastatic breast cancer (mBC) previously treated with two or more HER2-directed regimens. - Dai MS; Feng YH; Chen SW; Masuda N; Yau T; Chen ST; Lu YS; Yap YS; Ang PCS; Chu SC; Kwong A; Lee KS; et al. (Breast cancer research and treatment, 2021)